Turning Point Therapeutics Inc
Turning Point Therapeutics — Investor Presentation (May 2022)
53 slides from Turning Point Therapeutics's investor presentation, May 10, 2022
Slide 1: Next-Generation Precision Oncology Medicines Company Overview
Next-Generation Precision Oncology Medicines Company Overview May 2022 Exhibit 99.2
Slide 2: Forward-looking statements
Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development activities, plans and projected timelines, business strategy and plans, r
Slide 3: Turning Point Therapeutics Overview
¹ Cash, cash equivalents and marketable securities as of 31-Mar-2022. Turning Point Therapeutics Overview Turning Point’s vision is to be a leader in precision oncology, designing and developing novel targeted therapies for cancer treatment Portfolio of Potentially Differentiated Assets Addressing U
Slide 4: Strategic expansion of precision oncology portfolio with TPX-4589
Strategic expansion of precision oncology portfolio with TPX-4589 (formerly LM-302) license from LaNova Medicines Potential first-in-class anti-Claudin18.2 ADC targeting GI tumors Potential to broaden partnership by collaborating on up to three additional ADC programs Precision Oncology Strategy Rap
Slide 5: Ongoing Clinical Studies In Biomarker Driven Indications
Ongoing Clinical Studies In Biomarker Driven Indications DISCOVERY PRECLINICAL EARLY STAGE CLINICAL DEVELOPMENT LATE STAGE CLINICAL DEVELOPMENT ANTICIPATED NEXT STEPS REPOTRECTINIB (ROS1/TRK)¹ Pre-NDA meeting in 2Q22 Data updates from ROS1+ NSCLC and NTRK+ adv. solid tumor cohorts in 2H22 TRIDENT-1:
Slide 6: Patient population estimates and references
¹ Estimates rounded and include locally advanced and metastatic populations per SEER, based on incidence reported by American Cancer Society Cancer Facts & Figures 2021 (US) and GLOBOCAN 2020 (EU5). ² Zappa, et al: Transl Lung Cancer Res 2016. ³ Hirsch FR, et al: Lancet 2017. 4 Rosen EY, et al: Clin
Slide 7: Repotrectinib: A Highly Selective ROS1/TRK Inhibitor
Repotrectinib A Highly Selective ROS1/TRK Inhibitor
Slide 8: Repotrectinib: Potential Best-in-Class ROS1 and NTRK Targeted Therapy
Repotrectinib: Potential Best-in-Class ROS1 and NTRK Targeted Therapy in TKI-Naïve and Treatment Resistance Settings Highly potent, structurally differentiated: small (low molecular weight), compact, with a rigid 3D macrocycle Designed to bind completely inside the ATP pocket even in the presence of
Slide 9: Lead Candidate Repotrectinib: Best-in-Class Potential in ROS1+ NSCLC
Lead Candidate Repotrectinib: Best-in-Class Potential in ROS1+ NSCLC 3 BTDs Granted (2 in ROS1+ NSCLC and 1 in NTRK+ Adv. Solid Tumors) REPOTRECTINIB¹ XALKORI (CRIZOTINIB)³ ROZLYTREK (ENTRECTINIB)6 ROS1+ TKI-Naïve NSCLC cORR (95% CI) (95% CI) 79% (68, 88) n=71 66% (51, 79) n=50 74% (64, 83) n=92 TKI
Slide 10: Advancing Repotrectinib Toward Potential Registration
Potential best-in-class profile in ROS1+ NSCLC and NTRK+ advanced solid tumors, with a generally well tolerated safety profile Clinically meaningful efficacy in both TKI-naïve and TKI-pretreated patients, including those with G2032R solvent front mutation Targeting ~2% of NSCLC and ~0.3% of solid tu
Slide 11: TRIDENT-1 Phase 1/2 Study of Repotrectinib
TRIDENT-1 An Ongoing Phase 1/2 Study of Repotrectinib in Patients with Advanced Solid Tumors Harboring ROS1, NTRK1-3 Rearrangements
Slide 12: TRIDENT-1 Study Design and Preliminary Phase 1+2 Data
TRIDENT-1 Study Design and Preliminary Phase 1+2 Data ROS1+ ADVANCED NSCLC NTRK+ ADVANCED SOLID TUMORS EXP-1 ROS1 TKI-naïve (n=55) EXP-2 1 prior ROS1 TKI AND 1 platinum-based chemotherapy (n=60) EXP-3 2 prior ROS1 TKIs AND No prior chemotherapy (n=40) EXP-4 1 prior ROS1 TKI AND No prior chemotherapy
Slide 13: EXP-1: ROS1+ TKI-Naïve NSCLC Clinical Activity
EXP-1: ROS1+ TKI-Naïve NSCLC Clinical Activity Note: Data pooled across the Phase 1 and 2 portions of TRIDENT-1 with a data cutoff of 11-Feb-2022 with responses confirmed per RECIST 1.1 and assessed by blinded independent central review (BICR). Pooled Phase 1 and Phase 2 patients included those who
Slide 14: ROS1+ TKI-Naïve NSCLC: Duration of Response by Kaplan Meier
ROS1+ TKI-Naïve NSCLC: Duration of Response by Kaplan Meier EXP-1 EXP-2 EXP-3 EXP-4 EXP-5 EXP-6 DOR PARAMETER Repotrectinib¹ (N=56) Rozlytrek (entrectinib)² Xalkori (crizotinib)³ Median DOR 95% CI Not mature 15.7 months (13.9, 28.6) 18.3 months (12.7, NE) DOR Range (months) 1.4+-35.1+ 1.8-42.3 - % D
Slide 15: ROS1+ TKI-Naïve NSCLC: Progression Free Survival by Kaplan Meier
ROS1+ TKI-Naïve NSCLC: Progression Free Survival by Kaplan Meier EXP-1 EXP-2 EXP-3 EXP-4 EXP-5 EXP-6 PFS PARAMETER Repotrectinib¹ (N=71) Rozlytrek (entrectinib)² Xalkori (crizotinib)³ Median PFS 95% CI Not mature 15.7 months (11.0, 21.1) 19.2 months (14.4, NE) PFS Range (months) 0+-40.4+ Not disclos
Slide 16: EXP-2: ROS1+ TKI-Pretreated NSCLC Clinical Activity
Note: Data pooled across the Phase 1 and 2 portions of TRIDENT-1 with a data cutoff of 11-Feb-2022 with responses confirmed per RECIST 1.1 and assessed by blinded independent central review (BICR). Pooled Phase 1 and Phase 2 patients included those who received at least 1 dose of repotrectinib with
Slide 17: EXP-3: ROS1+ TKI-Pretreated NSCLC Clinical Activity
Note: Data pooled across the Phase 1 and 2 portions of TRIDENT-1 with a data cutoff of 11-Feb-2022 with responses confirmed per RECIST 1.1 and assessed by blinded independent central review (BICR). Pooled Phase 1 and Phase 2 patients included those who received at least 1 dose of repotrectinib with
Slide 18: EXP-4: ROS1+ TKI-Pretreated NSCLC Clinical Activity
Note: Data pooled across the Phase 1 and 2 portions of TRIDENT-1 with a data cutoff of 11-Feb-2022 with responses confirmed per RECIST 1.1 and assessed by blinded independent central review (BICR). Pooled Phase 1 and Phase 2 patients included those who received at least 1 dose of repotrectinib with
Slide 19: ROS1 G2032R Solvent Front Mutation Clinical Activity
Note: Of the TKI-pretreated patients, 10 did not have baseline evaluable information to determine presence of ROS1 G2032R solvent front mutation. Data pooled across the Phase 1 and 2 portions of TRIDENT-1 with a data cutoff of 11-Feb-2022 with responses confirmed per RECIST 1.1 and assessed by blind
Slide 20: NTRK+ TKI-Naïve Advanced Solid Tumors: Preliminary Clinical Activity
Note: Presented at AACR-NCI-EORTC Conference in Oct-2021. Data cutoff date 26-Aug-2021 for Phase 2 and 22-Jul-2019 for Phase 1. Phase 2: RECIST v1.1 assessed by Physician Assessment with a data cutoff date of 26-Aug-2021. Phase 1: RECIST v1.1 assessed by Blinded Independent Central Review (BICR) wit
Slide 21: NTRK+ TKI-Naïve Advanced Solid Tumors: Duration of Treatment
Note: Presented at AACR-NCI-EORTC Conference in Oct-2021. Patient on treatment for 30.7+ months has not had BICR assessment of scans since 22-Jul-2019; per physician assessment, patient was in response for 7.4 months. Phase 2 data cutoff date 26-Aug-2021 (responses confirmed by Physician Assessment)
Slide 22: NTRK+ TKI-Pretreated Adv. Solid Tumors: Preliminary Clinical Activity
Note: Presented at AACR-NCI-EORTC Conference in Oct-2021. *At time of the 26-Aug-2021 data cutoff, 3 patients in Phase 2 EXP-6 had unconfirmed PR (uPR). Two uPRs have been confirmed since the 26-Aug-2021 data cutoff and are included in the cORR; the third patient is on treatment awaiting a confirmat
Slide 23: NTRK+ TKI-Pretreated with NTRK Resistance Mutations: Clinical Activity
NTRK+ TKI-Pretreated Advanced Solid Tumors with NTRK Resistance Mutations: Preliminary Clinical Activity Note: Presented at AACR-NCI-EORTC Conference in Oct-2021. **At time of the 26-Aug-2021 data cutoff, 3 patients in Phase 2 EXP-6 with a resistance mutation had unconfirmed PR (uPR). Two uPRs have
Slide 24: NTRK+ TKI-Pretreated Advanced Solid Tumors: Duration of Treatment
Note: Presented at AACR-NCI-EORTC Conference in Oct-2021. Phase 2 data cutoff date 26-Aug-2021 (responses confirmed by Physician Assessment). Phase 1 data cutoff date 22-Jul-2019 for responses confirmed by BICR and 26-Aug-2021 for duration of treatment. NTRK+ TKI-Pretreated Advanced Solid Tumors: Du
Slide 25: Safety Summary: TRIDENT-1 Phase 1 and Phase 2 Combined
ALL TREATED PATIENTS (N=380) Adverse Reaction TEAES ≥ 15% subjects TRAES All Grades N (%) Grade 3 N (%) Grade 4 N (%) All Grades N (%) Grade 3 N (%) Grade 4 N (%) Dizziness 230 (60.5) 9 (2.4) 0 209 (55.0) 9 (2.4) 0 Dysgeusia 183 (48.2) 0 0 174 (45.8) 0 0 Constipation 135 (35.5) 1 (0.3) 0 89 (23.4) 0
Slide 26: Repotrectinib Combinations in KRAS-Driven Tumors
Repotrectinib Combinations in KRAS-Driven Tumors
Slide 27: Repotrectinib Selectivity Profile Potentially Expands Opportunity Beyond ROS1 and TRK
Inhibits JAK2, SRC and FAK Leads to suppression of STAT3 and AKT signaling, major mechanisms of resistance Demonstrated synergy with trametinib (MEK inhibitor) in mutant KRAS NSCLC, CRC and pancreatic cancer cell lines Demonstrated synergy with AMG510, inhibiting KRASG12C tumor cell proliferation, s
Slide 28: Repotrectinib/Trametinib Combination Exhibits Greater Tumor Growth Inhibition
Repotrectinib combination with trametinib is more effective than single-agent treatment in patient-derived KRAS mutant lung (KRAS G12D/V) and pancreatic (KRAS G12D/V/R) spheroid models Repotrectinib enhances trametinib efficacy in mutant KRAS G12D in vivo lung tumor models Overall, preclinical combi
Slide 29: Repotrectinib Enhances Survival with AMG510 in KRASG12C Xenograft Model
Repotrectinib combination shows a significant survival benefit in NSCLC KRASG12C xenograft model Builds on prior preclinical studies showing synergy with AMG510, inhibiting KRASG12C tumor cell proliferation, suppressing receptor tyrosine kinase upregulation, and reducing KRASG12C tumor cell cytokine
Slide 30: TRIDENT-2: Phase 1b/2 Study of Repotrectinib Combinations
TRIDENT-2: Phase 1b/2 Study of Repotrectinib Combinations for the Treatment of KRAS Mutant Cancers, Currently in Dose Finding Key Subject Entry Criteria: KRAS mutant advanced cancer (KRAS mutation type(s) to be defined for each cohort) Measurable disease per RECIST v1.1 Asymptomatic CNS disease allo
Slide 31: SHIELD-1: Phase 1 Study of Elzovantinib (TPX-0022)
SHIELD-1 An Ongoing Phase 1 Study of Elzovantinib (TPX-0022) in Patients with Advanced Solid Tumors Harboring Genetic Alterations in MET
Slide 32: SHIELD-1 Phase 1 Study Design
DOSE EXPANSION DOSE FINDING * Solid Tumors with MET Fusions or Oncogenic KD Mutations OR MET-amplified other than GI/NSCLC OR otherwise eligible for Cohorts I, III, or IV and >2 lines prior systemic therapy. BID, twice daily; CNS, central nervous system; CRC, colorectal cancer; GC, gastric cancer; G
Slide 33: Elzovantinib was generally well tolerated
Elzovantinib was generally well tolerated Most common TEAE was dizziness, likely due to off target TRK inhibition Dose modifications due to TEAE 21 (38.9%) patients with TEAEs leading to dose reduction 3 (5.6%) patients with TEAEs leading to drug discontinuation 2 DLTs at 120 mg QD* All Grade periph
Slide 34: Preliminary Efficacy by Investigator Assessment
Note: Presented at AACR-NCI-EORTC Conference in Oct-2021. Data cutoff date August 23, 2021. CBR = PR + SD CBR, clinical benefit rate; cORR, confirmed objective response rate; GC/GEJ, gastric cancer/gastroesophageal junction; NSCLC, non-small cell lung cancer; PD, progressive disease; PR, partial res
Slide 35: Preliminary Clinical Activity by Investigator Assessment
Note: 95% patients received prior Chemo/IO therapy DOR for 7 PRs were 15+, 12.9+, 9.2+, 5.6+, 5.6+, 5.2, and 1.8+ months MET amplification: 4 PRs (GCN: 7, 12, 14, and 25); 8 non-responders (GCN: n=6 had <10; n=1 had ≥6; n=1 had >13) Preliminary Clinical Activity by Investigator Assessment Note: Pres
Slide 36: Duration of Treatment
TKI-Naïve NSCLC and GC/GEJ Efficacy Evaluable Subjects (n=20) Duration of Treatment NSCLC (n=11): 3.4 weeks to 78.6+ weeks GC/GEJ (n=9) : 4.4 weeks to 68.1+ weeks Note: Presented at AACR-NCI-EORTC Conference in Oct-2021. Data cutoff date August 23, 2021. GC/GEJ, gastric cancer/gastroesophageal junct
Slide 37: SHIELD-2: Elzovantinib with Aumolertinib in EGFR Mutant MET-amplified NSCLC
SHIELD-2 Phase 1b/2 Study of Elzovantinib in Combination with Aumolertinib in EGFR Mutant MET-amplified Advanced Non-Small Cell Lung Cancer
Slide 38: SHIELD-2: Phase 1b/2 Study of Elzovantinib and Aumolertinib
CBR, clinical benefit rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression free survival; RP2D, recommended Phase 2 dose; TTR, time to response SHIELD-2: Phase 1b/2 Study of Elzovantinib and Aumolertinib in MET Amplified EGFRm NSCLC After Progression
Slide 39: SWORD-1: Study of TPX-0046 in RET Fusion or Mutation
An Ongoing Phase 1 Study of TPX-0046 in Patients with Advanced Solid Tumors Harboring RET Fusion or Mutation SWORD-1
Slide 40: TPX-0046 is a Potent Next Generation RET Tyrosine Kinase Inhibitor
Compact macrocycle with a small binding interface Potently inhibits wildtype RET and multiple RET mutations in cellular assays, demonstrates tumor regression in xenograft models VEGF sparing, potential to provide improved safety over approved agents Potential opportunity in TKI-naïve and TKI-pretrea
Slide 41: Phase 1/2 SWORD-1 Study Design of TPX-0046
* Additional doses and/or schedules may be explored. Phase 1/2 SWORD-1 Study Design of TPX-0046 in Patients with Advanced Solid Tumors Harboring RET Fusion or Mutation, Currently in Dose Finding Population Adults with advanced solid tumors RET fusion or mutation assessed by local testing No limit on
Slide 42: TPX-0046: Preliminary Safety Summary
TPX-0046 has been generally well tolerated Most AEs were Grade 1 or 2 Most common TEAE was dizziness Infrequent dose modifications due to TEAE 4 (19%) patients with TEAEs that led to dose reduction 2 (10%) patients with TEAEs that led to drug discontinuation MTD not reached; 1 DLT at 30 mg QD* No tr
Slide 43: TPX-0046: Preliminary Efficacy by Investigator Assessment
Of 5 RET TKI-naïve patients: 2 with confirmed PRs at 30 mg QD (DORs: 5.6 and 5.8+ months) Of 9 RET TKI-pretreated patients: 2 have stable disease with tumor reductions of -27% and -17% Both patients remained on treatment awaiting next scan TPX-0046: Preliminary Efficacy by Investigator Assessment No
Slide 44: A Next Generation ALK Inhibitor TPX-0131
A Next Generation ALK Inhibitor TPX-0131
Slide 45: TPX-0131: Highly Potent, CNS Penetrant ALK Inhibitor
TPX-0131 Differentiation Potently inhibit WT ALK, and multiple resistant mutations (solvent front, gatekeeper and compound) Solvent front mutation G1202R reported in ~42% of patient biopsies with a resistance mutation¹ Target Population Pretreated ALK+ NSCLC and other solid tumors Development Stage
Slide 46: Phase 1/2 FORGE-1 Study of TPX-0131 in ALK+ NSCLC
Study Endpoints: Primary: Evaluate safety / tolerability and determine maximum tolerated dose (MTD) and / or recommended Phase 2 dose (RP2D) Secondary: Objective Response Rate (ORR) by RECIST 1.1 Phase 1/2 FORGE-1 Study of TPX-0131 in Patients with ALK+ NSCLC, Currently in Dose Finding Phase 1 Dose
Slide 47: A Potentially First-in-Class Claudin18.2 ADC TPX-4589
A Potentially First-in-Class Claudin18.2 ADC TPX-4589 (FORMERLY LM-302)
Slide 48: Phase 1 Study of TPX-4589 in Advanced Solid Tumors
Phase 1 Study of TPX-4589 (formerly LM-302) in Advanced Solid Tumors, Currently in Dose Finding Study Endpoints: Primary Outcome Measure: Safety Secondary Outcome Measures: PK, efficacy and immunogenicity Efficacy Endpoints: ORR, DOR, DCR, PFS Phase 1 Dose Escalation / Expansion Subjects with advanc
Slide 49: Discovery Programs
© Turning Point Discovery Programs
Slide 50: Discovery Programs Focused on Dysregulated GTPase Signaling
Note: Figure adapted from Brito et al., Front. Cell Dev. Biol., 23, 2020. Discovery Programs Focused on Dysregulated GTPase Signaling, Which Plays a Central Role in Cancer Promotion and Progression PAK1/4 KRAS G12D Key downstream effectors RAF-MEK-ERK Established oncogenic driver Multi-tumor opportu
Slide 51: Anticipated 2022 Milestones
Anticipated 2022 Milestones
Slide 52: Anticipated 2022 Milestones
Repotrectinib Discuss topline ROS1+ NSCLC BICR data with the FDA at a pre-NDA meeting 2Q 2022 Present detailed study results from the ROS1+ NSCLC cohorts from TRIDENT-1 2H 2022 Provide a clinical data update from the NTRK+ advanced solid tumor cohorts from TRIDENT-1 2H 2022 Elzovantinib Initiate the
Slide 53: Next-Generation Precision Oncology Medicines Company Overview
Next-Generation Precision Oncology Medicines Company Overview May 2022
Turning Point Therapeutics — Investor Presentation (May 2022) on 6ix